Sven Bostyn

Publications

Bostyn, S.

Why a COVID IP Waiver Is not a Good Strategy

In: 2021.

(Abstract | Links | BibTeX)

Bostyn, S., Jongh, T. de, Poort, J., Radauer, A.

Effects of Supplementary Protection Mechanisms for Pharmaceutical Products

2018, (Rapport met Technopolis Group over beschermingsmechanismen op het gebied van intellectueel eigendom met betrekking tot medicijnen.).

(Links | BibTeX)

Bostyn, S.

Final report of the Expert Group on the development and implications of patent law in the field of biotechnology and genetic engineering

2016, (European Commission, Directorate General Internal Market, Industry, Entrepreneurship and SMEs (DG GROW).).

(Abstract | Links | BibTeX)

Bostyn, S.

Patentability of Plants: At the Crossroads between Monopolizing Nature and Protecting Technological Innovation?

In: The Journal of World Intellectual Property, (3-4), pp. 105-149, 2014.

(Abstract | Links | BibTeX)

Bostyn, S.

No Contact with the Human Body, Please! Patentability of Diagnostic Method Inventions after G01/04

In: European Intellectual Property Review, (6), pp. 238-244, 2007.

(Abstract | Links | BibTeX)

Bostyn, S.

DNA patents in Europe: Controversy remains

10.05.2005.

(Links | BibTeX)

Bostyn, S.

Patenting DNA sequences (polynucletides) and scope of protection in the European Union: an evaluation

2005.

(Links | BibTeX)

Bostyn, S.

Enabling biotechnological inventions in Europe and the United States: a study of the patentability of proteins and DNA sequences with special emphasis on the disclosure requirement

2005.

(Links | BibTeX)